Adagrasib oral

Phase 2

Mirati Therapeutics, Inc. (MRTX)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Advanced NSCLC

View Full Landscape

Drug Information

Target Indication

Advanced NSCLC

Clinical Trial

NCT05609578

Last updated: 10/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/5/2024

Krazati

Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRTX

Mirati Therapeutics, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

AdagrasibPhase 3

Carcinoma, Non-Small-Cell Lung

mFOLFOX6 RegimenPhase 3

Advanced Colorectal Cancer

SitravatinibPhase 3

Clear Cell Renal Cell Carcinoma

MRTX849Phase 3

Advanced Cancer

MRTX0902Phase 2

Solid Tumor

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts